Canakinumab shown to reduce rates of gout in atherosclerosis by more than half

(European League Against Rheumatism) The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half compared to placebo, regardless of baseline serum urate level.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news